A vs QGEN vs RGEN Stock Comparison

Agilent Technologies, Qiagen and Repligen Prices as of Oct 23, 2026 Peers: Industry group
1 more company in this comparison (TECH) Create a free account to keep reading and compare up to 10 companies.
A Agilent Technologies, Inc.
$173.05 +4.7% 1M +17.4% 1Y
Market cap
$49.59B
P/E
34.4x
Revenue (TTM)
$7.37B
Div. yield
0.01%
Life Sciences Tools Healthcare
6 wins
QGEN Qiagen N.V.
$50.38 +15.3% 1M -3.0% 1Y
Market cap
$10.94B
P/E
26.7x
Revenue (TTM)
$2.10B
Div. yield
–
Life Sciences Tools Healthcare
3 wins
RGEN Repligen Corp
$176.93 -4.1% 1M +7.1% 1Y
Market cap
$10.14B
P/E
244.2x
Revenue (TTM)
$785.10M
Div. yield
–
Life Sciences Tools Healthcare
2 wins

Head to Head

11 decided of 12

Agilent Technologies leads on 6 of the 12 questions below (Agilent Technologies 6, Qiagen 3, Repligen 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAQGENRGENLeader
Larger companyMarket capitalisation $49.59B $10.94B $10.14B A
Cheaper on earningsLower P/E, profitable companies only 34.4x 26.7x 244.2x QGEN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 26.5x 21.4x 91.2x QGEN
Faster revenue growthRevenue growth, trailing twelve months +8.6% +3.0% +16.5% RGEN
More profitableNet margin, trailing twelve months 19.5% 19.5% 5.3% A
Better return on capitalReturn on invested capital 13.1% 7.9% 1.9% A
Less leveragedLower net debt / EBITDA 1.1x 1.3x -1.6x RGEN
Higher dividend yieldTrailing dividend yield 0.01% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +17.4% -3.0% +7.1% A
Better 5-year returnAnnualised price return, 5 years +1.8%/yr -3.5%/yr -8.4%/yr A
Less volatileAnnualised volatility, 1 year 32.3% 35.8% 46.3% A
Higher overall scoreMean of the five percentile scores vs peers 62/100 71/100 66/100 QGEN

Percentile Scorecard

AQGENRGEN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAQGENRGEN
Valuation 57 #98 of 228 76 #56 of 228 53 #108 of 228
Growth 36 #143 of 222 29 #158 of 222 56 #98 of 222
Profitability 91 #20 of 210 93 #16 of 210 70 #63 of 210
Financial Health 55 #108 of 241 63 #90 of 241 80 #49 of 241
Shareholder Returns 69 #43 of 138 93 #10 of 138 70 #42 of 138
Overall 62 71 66
  • A ranked among 248 companies in Medical Devices and Diagnostics
  • QGEN ranked among 248 companies in Medical Devices and Diagnostics
  • RGEN ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAQGENRGENSPY
1 month +4.7%+15.3%-4.1% -1.0%
3 months +24.9%+21.7%+34.1% +2.9%
6 months +49.8%+31.2%+50.5% +6.4%
Year to date +27.2%+6.4%+8.0% +11.4%
1 year +17.4%-3.0%+7.1% +13.1%
3 years +63.8%+20.7%+26.6% +79.4%
3 years, per year +17.9%+6.5%+8.2% +21.5%
5 years +9.5%-16.4%-35.7% +67.7%
5 years, per year +1.8%-3.5%-8.4% +10.9%
10 years +279.7%+68.5%+504.9% +255.2%
10 years, per year +14.3%+5.4%+19.7% +13.5%

Risk

MeasureAQGENRGENSPY
Volatility, 1Y 32.3%35.8%46.3% 12.7%
Downside volatility, 1Y 27.5%30.5%46.9% 12.7%
Beta vs S&P 500, 1Y 0.860.451.18 1.00
Return / volatility, 1Y 0.54-0.080.15 1.03
Max drawdown, 5Y -39.6%-48.2%-66.2% -25.4%
From 52-week high -2.6%-9.5%-9.1% -2.5%
52-week high $177.72$55.66$194.57 $779.14
52-week low $110.24$32.63$102.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAQGENRGEN
P/E now vs peer median 33.9xmedian 30.7x 26.7xmedian 30.7x 240.3xmedian 30.7x
P/S now vs peer median 6.6xmedian 3.0x 5.2xmedian 3.0x 12.7xmedian 3.0x
EV/EBITDA now vs peer median 26.7xmedian 17.7x 18.1xmedian 17.7x 60.5xmedian 17.7x
P/FCF now vs peer median 38.5xmedian 23.7x 11.0xmedian 23.7x 89.2xmedian 23.7x
P/B now vs peer median 6.6xmedian 2.4x 3.3xmedian 2.4x 4.7xmedian 2.4x
PEG now vs peer median 3.45median 0.96 3.62median 0.96 -7.90median 0.96

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAQGENRGEN
Revenue $7.37B $2.10B $785.10M
Gross profit $3.97B $1.31B $422.67M
Operating income $1.64B $445.43M $64.61M
Net income $1.44B $409.32M $41.54M
Free cash flow $1.27B $991.33M $111.97M
R&D $485.00M $194.67M $56.17M
EPS (diluted) $5.09 $1.87 $0.73
Cash & equivalents $1.76B $768.50M $606.78M
Total debt $3.95B $6.86B $551.05M
Shares (diluted) 283.00M 218.88M 56.64M
Enterprise value $42.48B $6.71B $7.03B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAQGENRGEN
P/E 33.9x 26.7x 240.3x
P/FCF 38.5x 11.0x 89.2x
P/Operating cash flow 30.3x 16.7x 74.0x
P/S 6.6x 5.2x 12.7x
P/B 6.6x 3.3x 4.7x
P/Tangible book 7.6x 3.6x 5.7x
EV/EBITDA 26.7x 18.1x 60.5x
EV/EBIT 31.1x 26.4x 150.5x
EV/Revenue 6.9x 5.6x 12.4x
EV/FCF 40.2x 11.9x 86.9x
EV/Operating cash flow 31.7x 18.0x 72.1x
PEG (3Y EPS CAGR) 3.45 3.62 -7.90

Growth

14 metrics
MetricAQGENRGEN
Revenue growth (1Y) 8.6% 3.0% 16.5%
Revenue CAGR (3Y) 1.8% 2.0% 3.3%
Gross profit growth (1Y) 11.2% 1.7% 40.6%
Gross profit CAGR (3Y) 3.7% 1.3% 4.2%
Operating income growth (1Y) 13.5% -4.9% 370.8%
Operating income CAGR (3Y) 5.1% 3.3% -21.7%
Net income growth (1Y) 18.0% 143.9% 400.4%
Net income CAGR (3Y) 8.3% 6.7% -30.6%
EPS growth (1Y) 18.9% 12.5% 399.7%
EPS CAGR (3Y) 9.8% 7.4% -30.4%
Operating cash flow growth (1Y) 7.6% -3.0% 2.1%
Operating cash flow CAGR (3Y) -1.9% 8.0% -3.2%
Free cash flow growth (1Y) 16.5% 2.3% 2.8%
Free cash flow CAGR (3Y) -3.7% 10.5% 3.9%

Profitability

14 metrics
MetricAQGENRGEN
Gross margin 53.8% 62.2% 53.8%
EBITDA margin 25.9% 31.0% 20.5%
Operating margin 22.2% 21.2% 8.2%
Pretax margin 22.5% 22.0% 6.6%
Net margin 19.5% 19.5% 5.3%
FCF margin 17.2% 47.2% 14.3%
Operating cash flow margin 21.8% 31.2% 17.2%
Return on equity 19.9% 12.2% 2.0%
Return on assets 10.7% 7.0% 1.4%
Return on invested capital 13.1% 7.9% 1.9%
Return on capital employed 14.6% 8.5% 2.3%
Asset turnover 0.5x 0.4x 0.3x
Cash conversion (OCF / net income) 1.1x 1.6x 3.2x
Stock comp / revenue 1.8% 2.1% 4.2%

Financial Health

11 metrics
MetricAQGENRGEN
Debt / assets 28.3% 27.9% 18.7%
Debt / equity 0.5x 0.5x 0.3x
Net debt / EBITDA 1.1x 1.3x -1.6x
Debt / FCF 3.1x 1.7x 4.9x
Liabilities / assets 47.3% 43.0% 28.4%
Equity / assets 52.7% 57.0% 71.6%
Interest coverage 15.5x 11.3x 2.9x
Current ratio 2.1x 2.8x 9.1x
Quick ratio 1.4x 2.0x 7.3x
Cash ratio 0.8x 1.4x 6.1x
Altman Z-score 5.75 4.08 8.14

Shareholder Returns

7 metrics
MetricAQGENRGEN
Dividend yield 0.6% 5.2% –
Net buyback yield 0.6% 0.6% 0.0%
Shareholder yield 1.2% 5.8% 0.0%
Payout ratio (earnings) 19.9% – –
Payout ratio (FCF) 22.6% – –
Dividend growth (1Y) 2.1% – –
Dividend CAGR (3Y) 3.1% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAQGENRGEN
Forward P/E 26.5xFY2026 21.4xFY2026 91.2xFY2026
EPS, next fiscal year $6.54FY2026 $2.35FY2026 $1.94FY2026
EPS growth, next FY +17.0%FY2026 -1.3%FY2026 +13.5%FY2026
EPS growth, the year after +0.6% +17.9% +29.4%
Revenue, next fiscal year $7.87BFY2026 $2.25BFY2026 $772.56MFY2026
Revenue growth, next FY +15.3%FY2026 +7.8%FY2026 +4.6%FY2026
Revenue growth, the year after -5.6% -2.8% +35.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAQGENRGEN
Held by institutions 92.6% 67.3% 100.0%
Institutions holding 1,122 337 482
Change in shares held, QoQ +3.2% +16.5% +1.2%
Institutions buying 599 215 272
Institutions selling 350 86 141
Buyers to sellers 1.71 2.50 1.93

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AQGENRGEN
A 1.00 0.38 0.61
QGEN 0.38 1.00 0.39
RGEN 0.61 0.39 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, A, QGEN and RGEN?

Agilent Technologies (A) is the largest by market capitalisation: Agilent Technologies (A) $49.59B, Qiagen (QGEN) $10.94B, Repligen (RGEN) $10.14B.

Which stock is cheaper, A, QGEN and RGEN?

Qiagen (QGEN) trades on the lowest price-to-earnings ratio (Agilent Technologies (A) 34.4x, Qiagen (QGEN) 26.7x, Repligen (RGEN) 244.2x). On next year's consensus earnings, Qiagen (QGEN) is cheapest (Agilent Technologies (A) 26.5x, Qiagen (QGEN) 21.4x, Repligen (RGEN) 91.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Repligen (RGEN) grew revenue fastest over the trailing twelve months: Agilent Technologies (A) +8.6%, Qiagen (QGEN) +3.0%, Repligen (RGEN) +16.5%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Agilent Technologies (A) 19.5%, Qiagen (QGEN) 19.5%, Repligen (RGEN) 5.3%). On return on invested capital, Agilent Technologies (A) leads (Agilent Technologies (A) 13.1%, Qiagen (QGEN) 7.9%, Repligen (RGEN) 1.9%).

Which stock has performed better?

Over the past year Agilent Technologies (A) returned the most: Agilent Technologies (A) +17.4%, Qiagen (QGEN) -3.0%, Repligen (RGEN) +7.1%. Over five years, Agilent Technologies (A) compounded fastest (Agilent Technologies (A) +1.8%/yr, Qiagen (QGEN) -3.5%/yr, Repligen (RGEN) -8.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Agilent Technologies (A) 0.01%, Qiagen (QGEN) 0.00%, Repligen (RGEN) 0.00%. Qiagen (QGEN) and Repligen (RGEN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Agilent Technologies (A) has been the steadiest (Agilent Technologies (A) 32.3%, Qiagen (QGEN) 35.8%, Repligen (RGEN) 46.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, A, QGEN and RGEN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.